Bank of Hawaii Takes Position in Biogen Inc. $BIIB

Bank of Hawaii bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,667 shares of the biotechnology company’s stock, valued at approximately $1,173,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Empowered Funds LLC grew its position in shares of Biogen by 64.9% during the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after buying an additional 2,777 shares in the last quarter. Focus Partners Wealth increased its holdings in shares of Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after acquiring an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Biogen in the 2nd quarter valued at approximately $216,000. Cerity Partners LLC raised its position in shares of Biogen by 15.3% during the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after acquiring an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in Biogen by 13.4% during the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after purchasing an additional 316 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

Biogen stock opened at $196.58 on Friday. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $205.97. The firm’s 50 day simple moving average is $190.80 and its 200-day simple moving average is $184.89. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The company has a market cap of $29.02 billion, a P/E ratio of 21.09 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $3.02 EPS. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts predict that Biogen Inc. will post 13.89 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on BIIB. Rothschild & Co Redburn lifted their price objective on shares of Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. The Goldman Sachs Group raised their price target on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Mizuho decreased their price target on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating for the company in a report on Monday. Wall Street Zen raised shares of Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and raised their target price for the stock from $185.00 to $225.00 in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and a consensus target price of $217.37.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s planned RayThera acquisition expands its immunology pipeline with multiple anti-inflammatory assets, which could improve future growth opportunities and make the company less dependent on a single therapeutic area. Reuters article
• Positive Sentiment: Needham reiterated a Buy rating and set a $255 price target, signaling that some analysts see the deal as supportive of Biogen’s long-term earnings potential. TipRanks article
• Positive Sentiment: Morgan Stanley raised its price target on Biogen to $224 from $206, which may have helped reinforce bullish sentiment around the stock. Benzinga article
• Neutral Sentiment: Biogen shares were also reported to be outperforming peers even as broader healthcare stocks declined, suggesting relative strength rather than a company-specific selloff. MarketWatch article
• Negative Sentiment: An investor alert from Pomerantz LLP disclosed an investigation into claims on behalf of Biogen investors, which could add legal overhang and keep some pressure on sentiment. PR Newswire article

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.